Tango Therapeutics is advancing in cancer treatment with Phase 1/2 clinical trials for TNG908 and TNG462, targeting MTAP-deleted tumors. Tango's stock soared by over 100% following Mirati's ...
Tango Therapeutics, Inc. is a clinical-stage biotechnology company specializing in the discovery and development of novel cancer therapies using synthetic lethality. The company has a pipeline ...
Tango Therapeutics Inc (TNGX) reached a significant milestone as its stock price hit a 52-week high of 9.7 USD. This achievement reflects a remarkable 1-year change of 138.27%, underscoring the ...
Tango Therapeutics, Inc. (NASDAQ:TNGX) announced Friday it has entered into a new sales agreement with Leerink Partners LLC, allowing the company to sell up to $100 million of its common stock through ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback